Literature DB >> 18688673

Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy.

Ilhan Sezer1, Hilal Kocabas, Meltem Alkan Melikoglu, Mehmet Arman.   

Abstract

In recent years, biological agents have emerged as the most popular drugs for the treatment of rheumatoid arthritis (RA). The most frightening side effects of biological agents are infections, with tuberculosis being the leader. On account of the fact that biological agents have been used widespread, a number of algorithms have been developed to search latent tuberculosis. Among these algorithms, the most popular is the purified protein derivatives (PPD) test which is based upon late sensitivity reaction. The objective of this trial is to investigate the relevance of PPD response for the disease in RA patients. A total of 149 subjects (80 patients, 69 healthy), 35 RA patients who have not been treated before, 23 RA and 22 AS patients who are candidates for biological agents and being treated with immunosuppressive drugs, and 69 healthy subjects, have been included in this trial. Swelling joints, number of tender joints, visual analog scale, erythrocyte sedimentation rate, C-reactive protein, and rheumatoid factor were recorded. PPD was performed using the Mantoux method and was measured 72 h later. Statistically significant lower PPD values were determined in untreated RA patients compared to PPD values of treated RA and AS patients and healthy subjects. No correlation was determined between disease activity score 28 activity and PPD values in untreated and treated groups. Similarly, there was no correlation between acute phase reactants and PPD. Lower PPD responses in patients not being treated with immunosuppressive are due to the disease itself, rather than to the drugs being used. It is also important to interpret PPD results in early RA patients with suspicion, when it is intended to start anti tumor necrosis factor therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18688673     DOI: 10.1007/s10067-008-0982-1

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

Review 1.  Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2000-04       Impact factor: 21.405

2.  False tuberculin test results.

Authors:  G W Comstock
Journal:  Chest       Date:  1975-09       Impact factor: 9.410

3.  Mesenchymal stem cells and rheumatoid arthritis.

Authors:  Christian Jorgensen; Farida Djouad; Vanessa Fritz; Florence Apparailly; Pascale Plence; Danielle Noël
Journal:  Joint Bone Spine       Date:  2003-12       Impact factor: 4.929

Review 4.  Tuberculosis in the cytokine era: what rheumatologists need to know.

Authors:  Carol Dukes Hamilton
Journal:  Arthritis Rheum       Date:  2003-08

5.  Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Authors:  M L Prevoo; M A van 't Hof; H H Kuper; M A van Leeuwen; L B van de Putte; P L van Riel
Journal:  Arthritis Rheum       Date:  1995-01

Review 6.  The immunology of tuberculosis.

Authors:  T M Daniel
Journal:  Clin Chest Med       Date:  1980-05       Impact factor: 2.878

Review 7.  Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts.

Authors:  G S Panayi; V M Corrigall; C Pitzalis
Journal:  Rheum Dis Clin North Am       Date:  2001-05       Impact factor: 2.670

8.  Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis.

Authors:  D Ponce de León; E Acevedo-Vásquez; A Sánchez-Torres; M Cucho; J Alfaro; R Perich; C Pastor; J Harrison; C Sánchez-Schwartz
Journal:  Ann Rheum Dis       Date:  2005-09       Impact factor: 19.103

9.  A low prevalance of purified protein derivative test positivity in Turkish patients with rheumatoid arthritis. Association with clinical features and HRCT findings.

Authors:  I H Köker; O N Pamuk; C Karlikaya; N Tunçbilek; N Cakir
Journal:  Clin Exp Rheumatol       Date:  2007 Jan-Feb       Impact factor: 4.473

Review 10.  Aspects of early arthritis. Biological therapy in early arthritis--overtreatment or the way to go?

Authors:  Kei Ikeda; Sally Cox; Paul Emery
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  2 in total

1.  High incidence of intolerance to tuberculosis chemoprophylaxis.

Authors:  Muhammad Haroon; Una Martin; Joe Devlin
Journal:  Rheumatol Int       Date:  2010-07-24       Impact factor: 2.631

2.  Purified protein derivative test and its booster phenomenon in patients with rheumatoid arthritis.

Authors:  Mansour Salesi; Mohsen Meidani; Shirin Meshkinfar; Hurie Hashemi; Ziba Farajzadegan
Journal:  Adv Biomed Res       Date:  2015-05-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.